[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

3 clusters · 6 sources · 10 days · First seen · Last updated

Metabolic research for weight management

Overview

Research into metabolic weight management is expanding through new pharmacological approaches that differ from existing GLP-1 agonists.

Biotechnology company Enveda has reported that its experimental oral drug, ENV-308, successfully cleared a Phase 1 clinical trial involving 88 healthy adults with overweight or obesity. The drug is designed using AI to mimic the biochemical effects of physical activity by targeting Lac-Phe, a molecule that signals the brain to reduce appetite. While the natural molecule disappears quickly, ENV-308 is formulated as a once-daily pill intended to remain in the body longer.

Although the trial focused on safety rather than efficacy, researchers noted an “exceptional gastrointestinal safety profile” and suggested the drug may cause fewer adverse effects, such as nausea or vomiting, compared to existing GLP-1 therapies like semaglutide. Researchers intend to move toward Phase 2 trials to test the potential for weight maintenance.

In parallel, scientists at the University of California, Berkeley, are investigating the compound 5-tetradecyloxy-2-furoic acid (TOFA). Animal studies suggest TOFA may improve glucose levels and insulin sensitivity by affecting fat production and cellular energy mechanisms without significant loss of lean mass.

Entities

Enveda · Viswa Colluru · Stanford University · Lac-Phe · ENV-308

Timeline

  1. 12 days ago

    [HEALTH] 2 sources
    Enveda completes Phase 1 trial for exercise-mimicking pill

    Enveda's experimental drug ENV-308 has successfully passed Phase 1 clinical trials, showing it is safe and well-tolerated while mimicking the metabolic and appetite-suppressing effects of exercise.

  2. 21 days ago

    [HEALTH] 2 sources
    Researchers explore new metabolic pathways for weight management

    New research highlights two distinct weight-management approaches: the metabolic compound TOFA, which increases energy expenditure in mice, and Enveda’s ENV-308, an exercise-mimicking drug in human trials.

  3. 22 days ago

    [HEALTH] 2 sources
    Enveda's exercise-mimicking weight-loss pill clears Phase 1 trials

    Enveda’s experimental oral drug ENV-308 has cleared Phase 1 clinical trials, showing it is safe and well-tolerated in humans while mimicking the appetite-suppressing effects of exercise-induced Lac-Phe.

Sources

adevarul.ro · cancan.ro · doctorulzilei.ro · lavanguardia.com · lazybudgetchef.com · nypost.com

This summary has been updated 1 time: see revision history